

Indikation	Kurztitel	Vollständiger Titel
AMG-Studien		
Keimzelltumore	TIGER	TIGER- Eine randomisierte Phase-III-Studie zum Vergleich von konventionell dosierter Chemotherapie unter Einsatz von Paclitaxel, Ifosfamid und Cisplatin (TIP) mit hoch dosierter Chemotherapie unter Einsatz von mobilisierendem Paclitaxel plus Ifosfamid und in der Folge mit hoch dosiertem Carboplatin und Etoposid (TI-CE) als erste Salvagebehandlung bei rezidivierten oder refraktären Keimzelltumoren.
Seminom	SAKK 01/18 EudraCT number 2019-000514-11	Protocol SAKK 01/18 Reduced intensity radio-chemotherapy for stage IIA/B seminoma. A multicenter, open label phase II trial with two cohorts
Warm Autoimmune Hemolytic Anemia	MOM-M281-006 EudraCT number 2019-000720-17	Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double blind, Placebo controlled, Study with a Long-term Open label Extension
MCL	BeiGene BGB-3111-306 EudraCT number 2019-000413-36	A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
Immune Thrombocytopenia	XPAG-ITP EudraCT number 2019-002658-21	A Phase II, randomized (1:1) open label study to assess the efficacy and safety of eltrombopag in combination with dexamethasone compared to dexamethasone , as first-line treatment in adult patients with newly diagnosed immune thrombocytopenia (XPAG-ITP)
Chronic Primary Immune Thrombocytopenia	Takeda TAK-079-1004 EudraCT number 2019-004103-12	A Phase 2, Randomized, Double-Blind, Placebo -Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Persistent/Chronic Primary Immune Thrombocytopenia
Morb. Waldenström	CZAR-1 EudraCT number 2018-003526-88	Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström's Macroglobulinemia (CZAR-1)
Lower-risk MDS or CMML	Canfire EudraCT number	A Phase II, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Canakinumab for the Treatment of Anemia in Patients with IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes or CMML
B-cell Lymphoma	GOAL II EudraCT number 2019-002373-59	A prospective, multicenter randomized phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with or without Mor208 for patients with relapsed/refractory aggressive lymphoma

Sonstige Studien

AML	AML- Register	AML-Register und Biomaterialdatenbank der Studienallianz Leukämie (SAL) und der AML Cooperative Group (AML-CG)
ALL	GMALL-Register	GMALL-Register und Biomaterialbank Biomaterialsammlung und prospektive Datenerfassung zu Diagnostik, Behandlung und Krankheitsverlauf der ALL des Erwachsenen